OncologyPhase IPhase IIimmunotherapy neoantigen-based vaccinebiotech Case Study 20 March 2025 San Francisco Bay Area biotech advances Phase I-II cancer immunotherapy trial with Fortrea Download PDF Share Share Share on Facebook Share on Linkedin Share on Twitter Share on Threads Share via Email Copy link to clipboard